ZA200106725B - Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response. - Google Patents

Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.

Info

Publication number
ZA200106725B
ZA200106725B ZA200106725A ZA200106725A ZA200106725B ZA 200106725 B ZA200106725 B ZA 200106725B ZA 200106725 A ZA200106725 A ZA 200106725A ZA 200106725 A ZA200106725 A ZA 200106725A ZA 200106725 B ZA200106725 B ZA 200106725B
Authority
ZA
South Africa
Prior art keywords
antigen
antiparasitic
antiviral
generating
protein ompa
Prior art date
Application number
ZA200106725A
Other languages
English (en)
Inventor
Toufic Renno
Jean-Yves Bonnefoy
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of ZA200106725B publication Critical patent/ZA200106725B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA200106725A 1999-02-17 2001-08-15 Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response. ZA200106725B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9901917A FR2789588B1 (fr) 1999-02-17 1999-02-17 Utilisation d'une proteine ompa d'enterobacterie associee a un antigene dans une composition pharmaceutique destinee a generer ou accroitre une reponse cytotoxique antivirale, antiparasitaire ou antitumorale

Publications (1)

Publication Number Publication Date
ZA200106725B true ZA200106725B (en) 2002-04-24

Family

ID=9542129

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200106725A ZA200106725B (en) 1999-02-17 2001-08-15 Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.
ZA200106800A ZA200106800B (en) 1999-02-17 2001-08-17 Use of an OmpA enterobacterium protein associated with the elagigiltv peptide for treating melanomas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200106800A ZA200106800B (en) 1999-02-17 2001-08-17 Use of an OmpA enterobacterium protein associated with the elagigiltv peptide for treating melanomas.

Country Status (11)

Country Link
EP (2) EP1150707B1 (ja)
JP (2) JP2003506315A (ja)
CN (2) CN1191089C (ja)
AT (1) ATE293991T1 (ja)
AU (2) AU777511B2 (ja)
BR (2) BR0008305A (ja)
CA (2) CA2372059A1 (ja)
DE (1) DE60019725D1 (ja)
FR (1) FR2789588B1 (ja)
WO (2) WO2000048629A1 (ja)
ZA (2) ZA200106725B (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2803302B1 (fr) * 2000-01-04 2004-12-10 Pf Medicament Procede de preparation d'un polypeptide soluble en solvant aqueux en absence de detergent
FR2808445A1 (fr) * 2000-05-04 2001-11-09 Pf Medicament Proteine omp associee a un lysat de cellules tumorales autologues et/ou heterologues
WO2004011486A2 (fr) * 2002-07-26 2004-02-05 Pierre Fabre Medicament Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une response de type ctl antitumorale ou anti-infectieuse
FR2842811A1 (fr) * 2002-07-26 2004-01-30 Pf Medicament Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse
FR2842812A1 (fr) * 2002-07-26 2004-01-30 Pf Medicament Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse
JP5151349B2 (ja) * 2006-09-26 2013-02-27 東レ株式会社 免疫誘導剤及びその用途
EP2377883A1 (en) * 2010-04-15 2011-10-19 Universite d'Auvergne Clermont I Antagonists for the prevention or treatment of inflammatory bowel disease, and more particularly of Crohn's disease
US9314516B2 (en) * 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
CN110559424B (zh) * 2019-08-26 2021-08-20 君维安(武汉)生命科技有限公司 一种外膜蛋白在制备恶性肿瘤免疫治疗药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
FR2748476B1 (fr) * 1996-05-07 1998-08-14 Pf Medicament Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant

Also Published As

Publication number Publication date
CN1344166A (zh) 2002-04-10
AU777511B2 (en) 2004-10-21
BR0008307A (pt) 2002-01-22
JP2003506314A (ja) 2003-02-18
JP2003506315A (ja) 2003-02-18
CA2372059A1 (fr) 2000-08-24
CN1191089C (zh) 2005-03-02
FR2789588A1 (fr) 2000-08-18
DE60019725D1 (de) 2005-06-02
AU2809300A (en) 2000-09-04
BR0008305A (pt) 2002-01-22
AU2809400A (en) 2000-09-04
WO2000048628A1 (fr) 2000-08-24
WO2000048629A1 (fr) 2000-08-24
CA2362192A1 (fr) 2000-08-24
AU776903B2 (en) 2004-09-23
EP1150707B1 (fr) 2005-04-27
EP1150706A1 (fr) 2001-11-07
ZA200106800B (en) 2002-05-10
ATE293991T1 (de) 2005-05-15
CN1341029A (zh) 2002-03-20
EP1150707A1 (fr) 2001-11-07
CN1191090C (zh) 2005-03-02
FR2789588B1 (fr) 2001-05-04

Similar Documents

Publication Publication Date Title
MY140398A (en) 4-AMINO-6-PHENYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
MY136520A (en) Novel compounds
MY125978A (en) Admantane derivatives
DE69812159T2 (de) Derivate des adamantan
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
HK1024177A1 (en) Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
NZ504938A (en) Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen
ZA200106725B (en) Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
PL1718651T3 (pl) Pochodne 7H-pirolopirymidyny
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
PL357999A1 (en) Lhrh-antagonists, production and use thereof as medicament
TW200504051A (en) Novel acridine derivatives and their use as medicaments
AU2002360350A8 (en) Peptides that home to tumor lymphatic vasculature and methods of using same
HK1055562A1 (en) Medicament for the immunotherapy of malignant tumours
EP1011329A4 (en) PACLITAXELS 7-METHYLTHIOOXOMETHYLE AND 7-METHYLTHIODIOXOMETHYLE
WO2000030587A3 (fr) INHIBITEURS DE L'ACTIVATION DE NF-λB, ET LEURS UTILISATIONS PHARMACEUTIQUES
AU2001256440A1 (en) Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
WO1998050397A3 (de) Chimäre oligonucleotide und ihre verwendung
UA42462A (uk) Бромідний комплекс міді (іі) та кобальту (ііі) з діетаноламіном, що виявляє протипухлинну дію
GR1003969B (el) Σταθερα φαρμακευτικα διαλυματα νιμεσουλιδης.